Hemostemix Engages ProConsul to Boost Investor Engagement

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a clinical-stage biotechnology company, has engaged ProConsul Capital Ltd. to provide investment marketing consulting services, effective February 6th, 2025. This strategic move aims to enhance Hemostemix's visibility and attract new investors to its innovative blood-based stem cell therapeutics platform.

ProConsul will provide investment marketing consulting services to Hemostemix, with a monthly fee of $6,000 and stock options to be granted to ProConsul. The agreement operates on a month-to-month renewal basis, with either party able to terminate it with 30 days written notice. This collaboration aligns with Hemostemix's long-term growth strategy, as it seeks to scale its operations and expand its reach.

ProConsul's expertise in investment marketing and its network of investors, analysts, and other stakeholders can provide Hemostemix with access to a broader pool of capital and increased market exposure. This can help the company reach a larger audience of potential investors, including those who may not have been aware of Hemostemix previously. Additionally, ProConsul's strategic guidance on Hemostemix's capital markets activities can optimize its capital structure, timing, and terms of financings, leading to more efficient and successful capital raises.

Hemostemix's lead product, ACP-01, is an autologous cell therapy in Phase II clinical trial for the treatment of vascular diseases such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is in preclinical trial to evaluate its effect on neuropathic pain and motor function recovery. Hemostemix's patented blood-based stem cell therapeutics platform focuses on scaling angiogenic, neuronal, and cardiomyocyte cell precursors to treat no-option patients worldwide.



Hemostemix's engagement of ProConsul Capital is expected to have a positive impact on the company's ability to attract new investors and increase market visibility. ProConsul's expertise, network, strategic guidance, and the enhanced corporate governance and potential for institutional interest that come with the OTCQB listing can help Hemostemix effectively communicate its value proposition to potential investors. This can lead to better funding opportunities, liquidity, and broader market support, ultimately driving the company's growth and success.

In conclusion, Hemostemix's engagement of ProConsul Capital is a strategic move that aligns with the company's long-term growth strategy. By leveraging ProConsul's expertise, network, and strategic guidance, Hemostemix can enhance its visibility, attract new investors, and optimize its capital markets activities. This partnership has the potential to drive Hemostemix's growth and success in the competitive biotechnology sector.